<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945499</url>
  </required_header>
  <id_info>
    <org_study_id>DGE CEST MR and brain tumor</org_study_id>
    <nct_id>NCT04945499</nct_id>
  </id_info>
  <brief_title>The Application of Glucose CEST MR Imaging in Brain Tumor</brief_title>
  <official_title>The Evaluation of D-glucose Weighted Chemical Exchange Saturation Transfer (gluceoCEST)-Based Dynamic Glucose Enhanced(DGE) Magnetic Resonance Imaging（MRI） in Brain Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, natural D-glucose was suggested as a potential biodegradable contrast agent. The&#xD;
      feasibility of using D-glucose for dynamic perfusion imaging was explored to detect malignant&#xD;
      brain tumors based on blood brain barrier breakdown. Our study try to evaluate the&#xD;
      feasibility of dynamic glucose enhanced(DGE) magnetic resonance imaging（MRI）in brain tumor,&#xD;
      which based on D-glucose weighted chemical exchange saturation transfer (gluceoCEST).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      methods： Brain tumor patients were recruited. Time-resolved glucose signal changes were&#xD;
      detected using chemical exchange saturation transfer (glucoCEST) MRI. Dynamic glucose&#xD;
      enhanced (DGE) MRI was used to measure tissue response to an intravenous bolus of D-glucose.&#xD;
      During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous&#xD;
      infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile&#xD;
      solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed&#xD;
      using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times&#xD;
      of 250 seconds. Performing contrast enhancement based on Gd-DTPA in 30 minutes later, which&#xD;
      was used for comparison as golden standard.&#xD;
&#xD;
      The area of hyperintensity will be measured, which represents the area of brain tumor.&#xD;
&#xD;
      Differential test and Consistency analysis were used for statistical analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CEST value of tumor lesion including tumor core/ necrosis/ cysis/ edema</measure>
    <time_frame>1 week</time_frame>
    <description>the CEST value of tumor core and necrosis might higher than white matter</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>D-glucose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times 250 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-glucose</intervention_name>
    <description>using d-glucose as an contrast agent on CEST MR Imaging</description>
    <arm_group_label>D-glucose</arm_group_label>
    <other_name>50% dextrose injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have a brain mass consistent with a primary brain tumor or metastatic&#xD;
             brain tumor&#xD;
&#xD;
          -  able to give consent and willingness to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of any ferromagnetic implant (cardiac pacemakers, aneurysm clip, etc.)&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  claustrophobia or anxiety disorder&#xD;
&#xD;
          -  history of vertigo&#xD;
&#xD;
          -  persons with diabetes mellitus (self-report or HbA1C &gt;= 6.5%)&#xD;
&#xD;
          -  Sickle cell disease&#xD;
&#xD;
          -  persons taking prescription medicine for hypertension&#xD;
&#xD;
          -  blood iron deficiency (Hb concentration &lt; 11 g/dL or Hct &lt; 32%)&#xD;
&#xD;
          -  If volunteering for MRI: history of kidney disease and/or eGFR &lt; 60.&#xD;
&#xD;
          -  Middle-ear disorder&#xD;
&#xD;
          -  double vision&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  Multiple myeloma&#xD;
&#xD;
          -  Solid organ transplant&#xD;
&#xD;
          -  History of severe hepatic disease/liver transplant/pending liver transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhibo Wen, PhD</last_name>
    <phone>020-643461</phone>
    <email>zhibowen@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianhua Mo, MD</last_name>
    <phone>15627283832</phone>
    <email>154036203@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhibo wen, PhD</last_name>
      <phone>020-61643461</phone>
      <email>zhibowen@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dynamic glucose enhanced</keyword>
  <keyword>human brain tumor</keyword>
  <keyword>chemical exchange saturation transfer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT04945499/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

